Our top pick for
Exicure, Inc is a biotechnology business based in the US. Exicure shares (XCUR) are listed on the NASDAQ and all prices are listed in US Dollars. Exicure employs 57 staff and has a trailing 12-month revenue of around USD$16.8 million.
|52-week range||USD$0.9573 - USD$3.84|
|50-day moving average||USD$1.6686|
|200-day moving average||USD$2.1796|
|Wall St. target price||USD$11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.471|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$16.8 million|
|Gross profit TTM||USD$-18,044,000|
|Return on assets TTM||-15.59%|
|Return on equity TTM||-31.74%|
|Market capitalisation||USD$122.1 million|
TTM: trailing 12 months
There are currently 962,414 Exicure shares held short by investors – that's known as Exicure's "short interest". This figure is 3.3% down from 995,440 last month.
There are a few different ways that this level of interest in shorting Exicure shares can be evaluated.
Exicure's "short interest ratio" (SIR) is the quantity of Exicure shares currently shorted divided by the average quantity of Exicure shares traded daily (recently around 149443.16770186). Exicure's SIR currently stands at 6.44. In other words for every 100,000 Exicure shares traded daily on the market, roughly 6440 shares are currently held short.
However Exicure's short interest can also be evaluated against the total number of Exicure shares, or, against the total number of tradable Exicure shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Exicure's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Exicure shares in existence, roughly 10 shares are currently held short) or 0.0145% of the tradable shares (for every 100,000 tradable Exicure shares, roughly 15 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Exicure.
Find out more about how you can short Exicure stock.
We're not expecting Exicure to pay a dividend over the next 12 months.
Over the last 12 months, Exicure's shares have ranged in value from as little as $0.9573 up to $3.84. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exicure's is 1.498. This would suggest that Exicure's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes AST-008 that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; and XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; and license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome. The company was founded in 2011 and is based in Chicago, Illinois.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.